Endothelial ROBO4 suppresses PTGS2/COX-2 expression and inflammatory diseases.
Masato TanakaKeisuke ShirakuraYui TakayamaMiki ΜatsuiYukio WatanabeTakuya YamamotoJunya TakahashiShota TanakaNobumasa HinoTakefumi DoiMasanori ObanaYasushi FujioKazuo TakayamaYoshiaki OkadaPublished in: Communications biology (2024)
Accumulating evidence suggests that endothelial cells can be useful therapeutic targets. One of the potential targets is an endothelial cell-specific protein, Roundabout4 (ROBO4). ROBO4 has been shown to ameliorate multiple diseases in mice, including infectious diseases and sepsis. However, its mechanisms are not fully understood. In this study, using RNA-seq analysis, we found that ROBO4 downregulates prostaglandin-endoperoxide synthase 2 (PTGS2), which encodes cyclooxygenase-2. Mechanistic analysis reveals that ROBO4 interacts with IQ motif-containing GTPase-activating protein 1 (IQGAP1) and TNF receptor-associated factor 7 (TRAF7), a ubiquitin E3 ligase. In this complex, ROBO4 enhances IQGAP1 ubiquitination through TRAF7, inhibits prolonged RAC1 activation, and decreases PTGS2 expression in inflammatory endothelial cells. In addition, Robo4-deficiency in mice exacerbates PTGS2-associated inflammatory diseases, including arthritis, edema, and pain. Thus, we reveal the molecular mechanism by which ROBO4 suppresses the inflammatory response and vascular hyperpermeability, highlighting its potential as a promising therapeutic target for inflammatory diseases.
Keyphrases
- endothelial cells
- rna seq
- inflammatory response
- oxidative stress
- single cell
- binding protein
- signaling pathway
- poor prognosis
- infectious diseases
- rheumatoid arthritis
- high glucose
- chronic pain
- acute kidney injury
- type diabetes
- vascular endothelial growth factor
- intensive care unit
- pain management
- genome wide
- small molecule
- adipose tissue
- neuropathic pain
- lipopolysaccharide induced
- insulin resistance
- spinal cord injury
- climate change
- nitric oxide
- long non coding rna